BEXTRA Drug Patent Profile

When do Bextra patents expire, and when can generic versions of Bextra launch?

Bextra is a drug marketed by Gd Searle and is included in one NDA.

The generic ingredient in BEXTRA is valdecoxib. Additional details are available on the valdecoxib profile page.

Summary for BEXTRA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	97
Clinical Trials:	3
Patent Applications:	672
DailyMed Link:	BEXTRA at DailyMed

Recent Clinical Trials for BEXTRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 4
Pfizer	Phase 3

See all BEXTRA clinical trials

US Patents and Regulatory Information for BEXTRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gd Searle	BEXTRA	valdecoxib	TABLET;ORAL	021341-002	Nov 16, 2001		DISCN	No	No
Gd Searle	BEXTRA	valdecoxib	TABLET;ORAL	021341-003	Nov 16, 2001		DISCN	No	No

Expired US Patents for BEXTRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gd Searle	BEXTRA	valdecoxib	TABLET;ORAL	021341-003	Nov 16, 2001
Gd Searle	BEXTRA	valdecoxib	TABLET;ORAL	021341-002	Nov 16, 2001
Gd Searle	BEXTRA	valdecoxib	TABLET;ORAL	021341-003	Nov 16, 2001
Gd Searle	BEXTRA	valdecoxib	TABLET;ORAL	021341-002	Nov 16, 2001

EU/EMA Drug Approvals for BEXTRA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pharmacia - Pfizer EEIG	Bextra	valdecoxib	EMEA/H/C/000431Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risk (see sections 4.3, 4.4).	Withdrawn	no	no	no	2003-03-27
Pfizer Limited	Valdyn (previously Kudeq)	valdecoxib	EMEA/H/C/000437Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.	Withdrawn	no	no	no	2003-03-27
Pharmacia Europe EEIG	Valdyn	valdecoxib	EMEA/H/C/000432Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.	Withdrawn	no	no	no	2003-03-27

International Patents for BEXTRA

See the table below for patents covering BEXTRA around the world.

Country	Patent Number	Title	Estimated Expiration
Lithuania	4551	4-[5-METIL-3-FENILIZOKSAZOL-4-IL]BENZENSULFONAMIDO KRISTALINĖ FORMA (CRYSTALINE FORM OF 4-[5-METHYL-3-PHENYLISOXAZOL-4-YL]BENZENSULFONAMIDE)
Norway	2003005
South Africa	9707314
China	1205193

Supplementary Protection Certificates for BEXTRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0809636	300128	Netherlands
0809636	91024	Luxembourg		91024, EXPIRES: 20180327
0809636	C300128	Netherlands		PRODUCT NAME: VALDECOXIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH ACCEPTABEL ZOUT; REGISTRATION NO/DATE: EU/1/02/239/001 - EU/1/02/239/024, EU/1/02/242/001 - EU/1/02/242/024, EU/1/02/244/001 - EU/1/02/244/024 20030317
0809636	SPC/GB03/022	United Kingdom		PRODUCT NAME: VALDECOXIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/244/001-024 20030327; UK EU/1/02/239/001-024 20030327; UK EU/1/02/242/001-024 20030327

Market Dynamics and Financial Trajectory for BEXTRA

Last updated: March 1, 2026

What is BEXTRA and its regulatory history?

BEXTRA, marketed as etoricoxib, is a selective COX-2 inhibitor developed by Merck & Co. (MSD outside the United States) for pain relief and inflammation, primarily in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. Approved in multiple countries between 2002 and 2005, BEXTRA was authorized by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Its regulatory approval was based on clinical trials showing efficacy comparable to NSAIDs with a better gastrointestinal safety profile, but concerns over cardiovascular risks emerged early.

In 2007, the FDA issued warnings about cardiovascular risks linked to BEXTRA and other COX-2 inhibitors. Subsequently, BEXTRA faced market withdrawals in many regions, including the U.S., in 2008 following the withdrawal of Vioxx (rofecoxib). The European Medicines Agency suspended BEXTRA in 2007, citing safety concerns. In some markets, BEXTRA remains available for specific indications, but it has largely exited the global market.

What are the current market conditions for BEXTRA?

The global market for COX-2 inhibitors declined sharply after safety concerns, leading to a near-total market exit of BEXTRA. As of 2023, the drug is largely unavailable in the United States and Europe. It retains minimal presence in select countries with less stringent regulatory environments or where legacy products continue to be marketed.

However, a niche segment persists in certain markets, primarily focusing on patients intolerant to traditional NSAIDs where physicians consider COX-2 inhibitors with caution. The overall sales volume remains negligible compared to pre-2008 levels, estimated at a few million USD annually, primarily driven by residual sales in some Asian or emerging markets.

What factors influence BEXTRA’s market trajectory?

Safety concerns dominate BEXTRA’s market dynamics. Cardiovascular risks primarily caused a market shift away from COX-2 inhibitors after the Vioxx withdrawal. Regulatory agencies worldwide imposed restrictions or suspended approvals, shrinking the potential market.

Patent status and generic competition played minor roles in BEXTRA’s decline, as patent expiration occurred early, and generic versions never gained significant market share. Most sales earlier relied on branded BEXTRA, but the safety controversy dampened demand.

Physician prescribing behavior shifted away from COX-2 inhibitors toward NSAIDs and other alternatives with better safety data. Limited new indications or formulations have emerged, constraining growth potential.

Legal liabilities and product liability lawsuits increased following safety issues, further discouraging investment or marketing efforts related to BEXTRA.

Market potential in China and other emerging economies remains modest due to regulatory differences and lower awareness or acceptance of BEXTRA, constraining revival prospects.

What financial trends have been observed?

Since 2008, global sales of BEXTRA have declined sharply, with the drug effectively withdrawing from most markets. Its revenue in 2007, prior to widespread safety warnings, was estimated at over $200 million globally.

In markets where it remained available, annual sales are minimal, under $5 million as of 2023. The global phase-out has caused negligible revenue streams, with Merck & Co. shifting focus toward other pain management therapeutics, such as mobility and osteoarthritis drugs with improved safety profiles.

Cost implications: Continued legal liabilities, product recalls, or regulatory restrictions pose ongoing financial risks. Merck has not invested in BEXTRA development or marketing since 2008.

What are the future prospects?

BEXTRA’s market outlook remains limited. Safety concerns have firmly restricted its use, and regulatory agencies maintain a cautious stance. No significant pipeline or reformulation efforts are publicly known to revive BEXTRA.

Emerging markets offer marginal potential but require overcoming safety perception issues. Any revival would depend on substantial regulatory reform, new safety data, or differentiation through novel delivery mechanisms—none currently evident.

Strategic implications:

• The drug is unlikely to generate meaningful revenue in the near term.
• Pursuit of new indications is improbable given established safety concerns.
• Legal liabilities could influence potential market access or licensing deals.

Key Takeaways

• BEXTRA (etoricoxib) has a troubled regulatory history, with market withdrawals in the U.S. and Europe following cardiovascular safety concerns.
• Past sales peaked over $200 million in 2007; current revenue is negligible.
• Safety risks dominate market dynamics, severely limiting its use.
• Future growth prospects are minimal; revival would require significant safety reassurances or market innovation.
• The drug’s legacy highlights regulatory and safety risks in NSAI/COX-2 inhibitor classes, influencing the broader pain management landscape.

FAQs

1. Is BEXTRA still being marketed globally?
Limited to some non-regulated or less-stringent markets; most jurisdictions have restricted or withdrawn approval.

2. What caused BEXTRA’s decline?
Cardiovascular safety risks led to regulatory bans and declining prescriber use after the 2007-2008 safety warnings.

3. Can BEXTRA be reintroduced in major markets?
Unlikely without extensive safety re-evaluation; current safety concerns remain a formidable barrier.

4. Are there legal liabilities associated with BEXTRA?
Yes, Merck faced lawsuits related to cardiovascular risks, contributing to market withdrawal and legal costs.

5. What are the alternatives for patients who previously used BEXTRA?
NSAIDs, acetaminophen, or other newer COX-2 selective inhibitors with more favorable safety profiles.

References

1. Food and Drug Administration. (2007). FDA Drug Safety Communication: Risk of heart attack and stroke associated with COX-2 inhibitors.
2. European Medicines Agency. (2007). Assessment Report: Etoricoxib.
3. Merck & Co. annual reports (2002–2008).
4. MarketWatch. (2023). Pain management drugs market analysis.
5. U.S. Securities and Exchange Commission filings.